A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost ...

Maintaining treatment with CDK4/6 inhibitors significantly suppresses the growth of breast cancer cells, even after drug resistance has developed, according to new research.

Most youth who start puberty blockers progress to gender-affirming hormones, drugs that aim to induce desired sex characteristics like facial hair, or breast ... for females, estrogen for males ...

Limited to estrogen receptor-positive breast cancer (ER+) the compound addresses many common concerns with existing treatment ...

A Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

Jan. 25, 2025 — Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a ...

Breast cancer is the most common cancer in women, but it can also appear in men. Mutations in ESR1, which encodes estrogen receptor-α (ERα), drive resistance to approved endocrine therapies in ...

TWO women lose their lives to cervical cancer every day in the UK ... Taking the combined Pill for more than five years increases your risk further - but this risk drops as soon as you stop ...

According to Pro Football Focus, the return of Ar'maj Reed-Adams is a big one, solely based on the fact that he is the second-highest graded run blocker at offensive guard. At 82.4, he is only ...